论文信息 - Osteoprotegerin and Insulin Resistance in Childhood Obesity: A New Interplay?

Osteoprotegerin and Insulin Resistance in Childhood Obesity: A New Interplay?

www.postersession.com Childhood obesity constitutes a phenomenon with epidemic prevalence in a worldwide context, leading to significant increase in the prevalence of metabolic co-morbidities. Osteoprotegerin (OPG) is α tumor necrosis factor receptor superfamily glucoprotein that is acting as a decoy receptor for receptor activator of nuclear factor kappa B ligand (RANKL) with an anti-resoptive bone effect. Lately, it has been reported a positive association between OPG levels and cardiovascular morbidity and mortality1-2. Additionally, there is evidence that OPG in obese adults participates in the pathogenesis of atherosclerosis and cardiovascular diseases by promoting inflammation, which is known to be linked to insulin resistance (IR)3-4. Data regarding the relationship among obesity, insulin resistance and OPG in children and adolescents are sparse5. The aim of the study was to assess serum OPG levels in obese children and adolescents and explore any possible associations with insulin resistance. Osteoprotegerin and insulin resistance in childhood obesity: a new interplay?

[1] K. Zhu,et al. Elevated Circulating Osteoprotegerin and Renal Dysfunction Predict 15-Year Cardiovascular and All-Cause Mortality: A Prospective Study of Elderly Women , 2015, PloS one.

[2] W. Shimizu,et al. Osteoprotegerin is Associated With Endothelial Function and Predicts Early Carotid Atherosclerosis in Patients With Coronary Artery Disease. , 2015, International heart journal.